NCT05851378View on ClinicalTrials.gov

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Adult Gliomas, Mixed
Interventions
DRUG

Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)

Given intravenously at time of imaging

PROCEDURE

Magnetic Resonance Image (MRI)

Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Robert Bok, MD, PhD

OTHER